VAXX News and Press, Vaxxinity Inc. From 01/17/23

Summary We may not be at the end credits for COVID-19 virus. Shares of Vaxxinity, Inc., like most biotechs, have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geopolitical. In the meantime, the company has been taking care of its COVID-19...

DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at t...

Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZenec...

Shares of Vaxxinity (NASDAQ: VAXX) were up 36.8% this week as of Thursday's close. The stock closed last week at $1.74. Vaxxinity's shares opened on Monday at $1.70 and then soared on Thursday to $3.95 before dropping a bit to $2.38 by Thursday's close. The stock has a 52-week low of $1.2...

The following slide deck was published by Vaxxinity, Inc. in conjunction with this event. For further details see: Vaxxinity (VAXX) Analyst and R&D Day - November 2022

Vaxxinity press release ( NASDAQ: VAXX ): Q3 GAAP EPS of -$0.15 in-line. As of September 30, 2022, the Company had $102.2 million of cash and cash equivalents and short-term investments, as compared to $145.1 million on December 31, 2021. For further details see: ...

Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates UB-612 COVID-19 Vaccine Completes Enrollment in Pivota...

Featuring subject matter experts in neuroscience, migraine and hypercholesterolemia DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it will hos...

DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the follo...

UB-612 Phase 3 topline data readout expected in 4Q22 DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that enrollment is complete for its global Phase 3...